StockNews.com Initiates Coverage on OpGen (NASDAQ:OPGN)

StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a research note issued to investors on Monday morning. The firm issued a sell rating on the medical research company’s stock.

OpGen Price Performance

NASDAQ OPGN opened at $2.40 on Monday. The business has a fifty day simple moving average of $1.18 and a 200 day simple moving average of $1.43. OpGen has a 12 month low of $0.53 and a 12 month high of $9.90.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.